Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Micro-XASX:MX1 3-Year EBITDA Growth Rate is 16.80% as of Dec. 2025, which is 15% below its 10-year median of 19.70. The stock has 4 warning signs investors should review. Among 690 Medical Devices & Instruments companies, Micro-X ranks better than 61.74% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.80% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 13.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Micro-X was 35.90% per year. The lowest was 16.20% per year. And the median was 19.70% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Micro-X 3-Year EBITDA Growth Rate Related Terms
ASX:MX1 vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Micro-X's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Micro-X 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Micro-X's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Micro-X's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.80% mean?
Micro-X (ASX:MX1) has a 3-Year EBITDA Growth Rate of 16.80% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Micro-X and its competitors. This is 15% below median its historical median of 19.70. Over the past decade, Micro-X's 3-Year EBITDA Growth Rate has ranged from 16.20 to 35.90. According to the industry distribution chart, Micro-X ranks #264 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 38.3%.
Is Micro-X's 3-Year EBITDA Growth Rate too high?
Micro-X's current 3-Year EBITDA Growth Rate of 16.80% is 15% below median its 10-year median of 19.70. Over the past 10 years, this metric has ranged from a low of 16.20 to a high of 35.90. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 8.20. Micro-X's value of 16.80% is 104.9% above this industry median. Based on the distribution chart, Micro-X ranks #264 out of 690 companies in the Medical Devices & Instruments industry, which is above the industry midpoint.
How does Micro-X's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Micro-X ranks #264 out of 690 companies for 3-Year EBITDA Growth Rate. This puts Micro-X in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.20. Micro-X's value of 16.80% is 104.9% above this benchmark. Historically, Micro-X's own 3-Year EBITDA Growth Rate has ranged from 16.20 to 35.90 over the past decade. While the company's 10-year median is 19.70 vs. the industry median of 8.20, Micro-X has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 8.20, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Micro-X's current 3-Year EBITDA Growth Rate of 16.80% is 104.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Micro-X and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 8.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Micro-X's current 3-Year EBITDA Growth Rate is 16.80%, which is 15% below median its own 10-year median of 19.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Micro-X stock overvalued right now?
Based on GuruFocus' analysis, Micro-X (ASX:MX1) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.11, compared to a current price of A$0.03 — trading 75.5% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 16.80%, which is 15% below median its 10-year median of 19.70 and 104.9% above the Medical Devices & Instruments industry median of 8.20. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Micro-X (ASX:MX1), the current 3-Year EBITDA Growth Rate is 16.80% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Micro-X Ltd operates in the medical industry. The company is engaged in the design, development, manufacturing, and commercialisation of imaging products for the healthcare and security markets utilising Micro-X's proprietary cold cathode X-ray technology. Its products include Head CT, Rover, Argus, Checkpoints, and Baggage CT Scanner imaging devices. In addition, the group also offers custom imaging solutions based on the specific requirements of its customers. Its geographical operating segments are the United States, which generates maximum revenue, and Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:MX1 has been successfully added to your 
